Filip Jankú

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 28 papers. Top paper: “Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial”.

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0611

N/A

4.8DataRank · unranked

264 citations

Marta Peñas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Jankú +16 more

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000347

N/A

4.0DataRank · unranked

131 citations

Funda Meric‐Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar, Jordi Rodon Ahnert +35 more

Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors

The Oncologist(2021)10.1002/onco.13682

N/A

1.4DataRank · unranked

47 citations

Henry Hiep Vo, Vivek Subbiah, Filip Jankú, Sarina A. Piha‐Paul, Bülent Yılmaz +7 more

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1215

N/A

1.3DataRank · unranked

41 citations

Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah +17 more

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

Investigational New Drugs(2021)10.1007/s10637-020-01035-9

N/A

1.2DataRank · unranked

32 citations

D. Liu, Michael Offin, Cecilia Lezcano, Jean Torrisi, Sheldon L. Brownstein +13 more

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Cancer Research Communications(2023)10.1158/2767-9764.crc-22-0260

N/A

0.943DataRank · unranked

37 citations

Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Jankú, Jordi Rodón +13 more

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

npj Precision Oncology(2022)10.1038/s41698-022-00317-0

N/A

0.607DataRank · unranked

17 citations

Siqing Fu, David S. Hong, Daniel D. Karp, Sarina A. Piha‐Paul, Vivek Subbiah +18 more

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Scientific Reports(2022)10.1038/s41598-022-16588-3

N/A

0.375DataRank · unranked

4 citations

David S. Hong, Christine B. Peterson, Bettzy Stephen, Ecaterina E. Dumbrava, Shubbam Pant +18 more

Associations between the gut microbiome and fatigue in cancer patients

Scientific Reports(2021)10.1038/s41598-021-84783-9

N/A

0DataRank · unranked

45 citations

Tito R. Mendoza, Liangliang Zhang, Siqing Fu, Sarina A. Piha‐Paul, David S. Hong +10 more

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

Scientific Reports(2021)10.1038/s41598-021-83317-7

N/A

0DataRank · unranked

35 citations

Amir A. Jazaeri, Pamela T. Soliman, Nicole D. Fleming, Jing Gong, Sarina A. Piha‐Paul +4 more

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study

npj Precision Oncology(2021)10.1038/s41698-021-00159-2

N/A

0DataRank · unranked

27 citations

David S. Hong, Siqing Fu, Daniel D. Karp, Sarina A. Piha‐Paul, Merrill S. Kies +16 more

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma

ESMO Open(2021)10.1016/j.esmoop.2021.100357

N/A

0DataRank · unranked

26 citations

Jiří Polívka, Hong Huang, I. Treskova, Kristýna Pivovarčíková, T. Fikrle +7 more

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

ESMO Open(2021)10.1016/j.esmoop.2021.100079

N/A

0DataRank · unranked

13 citations

Ruth Sacks, Ishwaria M. Subbiah, Neele Drobnitzky, Sarina A. Piha‐Paul, David S. Hong +15 more

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

OncoTargets and Therapy(2021)10.2147/ott.s291801

N/A

0DataRank · unranked

3 citations

Ecaterina E. Dumbrava, Binoj C. Nair, Wendy Xiong, Xu Li, Rosa Mostorino +12 more

Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.07.004

N/A

0DataRank · unranked

2 citations

Andrew W. Hahn, Pavlos Msaouel, Funda Meric‐Bernstam, Nathaniel R. Wilson, Aung Naing +18 more

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Scientific Reports(2022)10.1038/s41598-022-12669-5

N/A

0DataRank · unranked

24 citations

Funda Meric‐Bernstam, David S. Hong, Filip Jankú, Aung Naing, Sarina A. Piha‐Paul +13 more

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

npj Precision Oncology(2023)10.1038/s41698-022-00341-0

N/A

0DataRank · unranked

22 citations

Jason Roszik, Filip Jankú, David S. Hong, Shumei Kato, Aung Naing +11 more

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery`

Oncoscience(2023)10.18632/oncoscience.586

N/A

0DataRank · unranked

2 citations

Filip Jankú, Neeta Somaiah, Kelly K. Hunt, Sireesha Yedururi, Vivek Subbiah +1 more

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3952

N/A

0DataRank · unranked

7 citations

Filip Jankú, Siqing Fu, Ecaterina E. Dumbrava, David S. Hong, Daniel D. Karp +20 more

Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3531

N/A

0DataRank · unranked

3 citations

Filip Jankú, Ying Yuan, Leylah Drusbosky, Alice P. Chen, Xiaofeng Zheng +15 more

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

Scientific Reports(2020)10.1038/s41598-020-58366-z

N/A

0DataRank · unranked

20 citations

Filip Jankú, Sarina A. Piha‐Paul, Kenneth R. Hess, Russell R. Broaddus, Lidong Liu +11 more

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss

Oncotarget(2020)10.18632/oncotarget.27503

N/A

0DataRank · unranked

24 citations

Ming Zhao, Argun Akçakanat, Kurt W. Evans, Erkan Yuca, Ecaterina Ileana Dumbrava +3 more

RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients

Journal of Cancer(2020)10.7150/jca.43729

N/A

0DataRank · unranked

13 citations

Helen J. Huang, Jing Ma, Yafei Wang, Zeng Cao, George Karlin‐Neumann +3 more

Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0751

N/A

0DataRank · unranked

11 citations

Andrew W. Hahn, Pavlos Msaouel, Alexander Andreev-Drakhlin, Funda Meric‐Bernstam, Aung Naing +17 more

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

Cancers(2021)10.3390/cancers13143600

N/A

0DataRank · unranked

93 citations

Filip Jankú, Razelle Kurzrock, Jacob J. Adashek

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

British Journal of Cancer(2021)10.1038/s41416-020-01230-8

N/A

0DataRank · unranked

43 citations

Filip Jankú, Vivek Subbiah, John Stewart, Sapna P. Patel, Ahmed O. Kaseb +10 more

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

ESMO Open(2021)10.1016/j.esmoop.2021.100230

N/A

0DataRank · unranked

41 citations

S. Greg Call, Helen J. Huang, A.L. Stuckett, Kiran Madwani, Abha Adat +16 more